Enasidenib induced differentiation of various types of leukemic cells expressing mutant IDH2, such as mutant IDH2 TF-1 erythroleukemic cells, primary human AML cells ex vivo, four IDH2-R140Q-mutant human AML xenografts mouse models in vivo [143]. The gene discussed is IDH2; the disease is acute myeloid leukemia.